Se ha denunciado esta presentación.
Utilizamos tu perfil de LinkedIn y tus datos de actividad para personalizar los anuncios y mostrarte publicidad más relevante. Puedes cambiar tus preferencias de publicidad en cualquier momento.

Hemp Oil: What Can It Do For You? Lebanon, TN 04 06 2018

417 visualizaciones

Publicado el

In this presentation, Dr. Cady reviews the peer-reviewed medical literature for the endocannibinoid system, the concept of endocannibinoid deficiency syndrome (now well established), and citations dealing with the multiplicity of health conditions for which a full spectrum hemp oil should be considered as a reasonable supportive strategy. The difference between the generic "CBD Oil" that is available at health food stores compared to the Zilis products is touched on. The Zilis products appear to have better absorbability, faster onset of action, and scientific studies elucidating the true duration of action of CBD levels in blood serum.

This presentation was given to a very appreciative audience at the Friendship Church in Lebanon, TN (a suburb of Nashville).

Publicado en: Salud y medicina
  • Sé el primero en comentar

  • Sé el primero en recomendar esto

Hemp Oil: What Can It Do For You? Lebanon, TN 04 06 2018

  1. 1. Louis B. Cady, MD, FAPA – CEO & Founder – Cady Wellness InstituteLouis B. Cady, MD, FAPA – CEO & Founder – Cady Wellness Institute Adjunct Clinical Lecturer – Indiana University School of Medicine Department of Psychiatry Functional & Integrative Medicine – Evansville, Indiana Hemp Oil: What Can It Do For You? April 6, 2018
  2. 2. Disclaimer: Zilis full spectrum hemp oil is not FDA approved for the diagnosis, treatment, prevention, or cure of ANY disease or “medical condition.” This type of non-THC containing hemp oil MAY be appropriate to support the structure and function of the human body.
  3. 3. Hemp • One of the oldest known cultivated plants • 12,000 years of usage • Used for clothes, soap and rope • Has a wide array of nutrients in it of almost all sources. • Medicinal use: 6,000 years • 3rd most prescribed medicinal agent for 60 years prior to its prohibition in 1937
  4. 4. 4,382 results – Feb 2, 2018 6:26 am4,382 results – Feb 2, 2018 6:26 am
  5. 5. 2/3/18 - 57 already * Search on “endocannabinoid system” www.pubmed.gov March 4, 2018 3/4/2018 - 103 4,417 citations as of 3/4/18 4/6/2018 - 130
  6. 6. Study: evaluate CB1 ligands + other agents “that possess antidepressant potential.” CONCLUSIONS: “The simultaneous modulation of the cannabinoid system and supplementation of magnesium or zinc produce at least additive antidepressant-like effect.” Study: evaluate CB1 ligands + other agents “that possess antidepressant potential.” CONCLUSIONS: “The simultaneous modulation of the cannabinoid system and supplementation of magnesium or zinc produce at least additive antidepressant-like effect.”
  7. 7. The results of the present study suggest that CB1r, CB2r, and MAGL are closely related to the neuropathological processes of PD. Therefore, the pharmacological modulation of these targets could represent a new potential therapeutic tool for the management of PD. The results of the present study suggest that CB1r, CB2r, and MAGL are closely related to the neuropathological processes of PD. Therefore, the pharmacological modulation of these targets could represent a new potential therapeutic tool for the management of PD.
  8. 8. Smith SC. Neuro Endocrinol Lett. 2014;35(3):198-201. Smith SC. Neuro Endocrinol Lett. 2014;35(3):198-201. CONCLUSION: Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. Clinical experience is bearing this out. Further research and especially, clinical trials will further demonstrate the usefulness of medical cannabis. As legal barriers fall and scientific bias fades this will become more apparent. CONCLUSION: Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. Clinical experience is bearing this out. Further research and especially, clinical trials will further demonstrate the usefulness of medical cannabis. As legal barriers fall and scientific bias fades this will become more apparent.
  9. 9. SEVERAL INTERVENTIONS UPREGULATE THE ECS SYSTEM: •Analgesics, anti-inflammatories •Antidepressants, antipsychotics, anxiolytics, anticonvulsants •Massage and manipulation •Acupuncture •Dietary supplements and herbal medicines. SEVERAL INTERVENTIONS UPREGULATE THE ECS SYSTEM: •Analgesics, anti-inflammatories •Antidepressants, antipsychotics, anxiolytics, anticonvulsants •Massage and manipulation •Acupuncture •Dietary supplements and herbal medicines. McPartland JM et al. PLoS One. 2014, Mar 12;9(3):e89566 McPartland JM et al. PLoS One. 2014, Mar 12;9(3):e89566
  10. 10. Getting high on cannabis makes you less likely to work hard for money, study says – The Independent Sept 1, 2016 http://www.independent.co.uk/news/science/cannabis-marijuana- weed-effects-getting-high-working-hard-money-motivation- a7220441.html
  11. 11. Way back in April 14-15, 1912
  12. 12. Purdue University & Mr. Fred A. Miler, botanist to Eli Lilly & Co. partner for “medicinal extract of Hemp (CBD) Research,” c. 1912-13
  13. 13. Endocannibinoid system – the body’s primary tool of homeostasis • Most significant neurotransmitter system in the body • Regulates & balances: – Nerve function, stress recovery, inflammation levels, immune function, energy intake and storage, cell life- cycles/apoptosis/reproduction, circulatory ystem
  14. 14. Endogenous cannabinoids • Synthesized in OUR body: ENDOcannabinoids – 2-AG (2-arachidonylgylerol) – Anadamide (N-arachidonoylethanolamine “AEA”) • These are fatty acid neurotransmitters • 2-AG – most abundant endocannabinoid in the body • Regulates appetite, immune function, pain signals, energy storage, among others
  15. 15. The endocanninoid receptors by the numbers… • CB1 – Brain spinal cord, reproductive & connective tissues • CB2 – Modulates immune system. Found on spleen, tonsils, thymus, all white blood cells (receptors) • T cells, B-eta cells, macrophages • GPR55 – linked to bone development and cancer cell proliferation
  16. 16. Endocannabinoids 101 • YOU make ENDO-cannabinoids – 2-AG (2 arachidonoylglycerol) • Most abundant • Regulates appetite, immune function, pain signals, energy storage. – Anandamide (N-arachidonoylethanolamine “AEA”) • HEMP plant makes PHYTO-cannabinoids – Interacts well with human CB receptors.
  17. 17. • Circulating eCB’s in humans, dogs, and ferrets measured before and after treadmill exercise. • “We show that humans and dogs shaire significantly increased exercise-induced eCB signaling following high- intensity endurance running. • eCB’s are “a neurobiological reward for endurance exercise.”
  18. 18. CECD: Clinical endocannabinoid deficiency • Implicated in many hard-to-treat disease states: – Fibromyalgia – Chronic migraines – Depression/anxiety – Irritable bowel syndrome Russo EB. Neuro End Lett 2008 April; 29(2): 192-200.
  19. 19. Anandamide • From Sanskrit for “bliss” or “happiness.” • Regulates pleasurable activities – food intake, reproduction, sleep, and pain relief • Found in mother’s milk, chocolate, and release during ovulation • Produced during meditation, yoga, and causes RUNNER’S HIGH. • A “bridge” between mind and body.
  20. 20. But what happens if you don’t make enough??? 57 citations 03 04 2017
  21. 21. 57 citations 04/06/ 2017“Deficits in signaling mediated by the endocannabinoid 2-AG have been reported in mouse models of autism spectrum disorder.” “Deficits in signaling mediated by the endocannabinoid 2-AG have been reported in mouse models of autism spectrum disorder.” “Deficits in social interaction, excessive grooming, decreased exploration of environment...” “Deficits in social interaction, excessive grooming, decreased exploration of environment...” “MOA” – “increased glutamatergic drive, which is consistent with a loss of retrograde feedback inhibition.” “MOA” – “increased glutamatergic drive, which is consistent with a loss of retrograde feedback inhibition.”
  22. 22. B “Endocannabinoid deficiency syndrome” – 2001 •“In certain conditions, whether congenital or acquired, endocannabinoid tone becomes deficient and productive of pathophysiological syndromes.” •many brain disorders are based on deficient neurotransmitters. “Endocannabinoid deficiency syndrome” – 2001 •“In certain conditions, whether congenital or acquired, endocannabinoid tone becomes deficient and productive of pathophysiological syndromes.” •many brain disorders are based on deficient neurotransmitters.
  23. 23. 19 results April 5, 201819 results April 5, 2018 • Stimulating ECS: • Reduction in alcohol consumption with +ECS input • Antihyperalgesic activities of EC in Mouse Model of neuropathic pain • Effects in migraine, fibromyalgia, irritable bowel, and “other treatment-resistant syndromes” (Russo EB, 2016) • CB2 deficient mice have pro-inflammatory obesity • Stimulating ECS: • Reduction in alcohol consumption with +ECS input • Antihyperalgesic activities of EC in Mouse Model of neuropathic pain • Effects in migraine, fibromyalgia, irritable bowel, and “other treatment-resistant syndromes” (Russo EB, 2016) • CB2 deficient mice have pro-inflammatory obesity
  24. 24. “Ethan B. Russo's paper of December 1, 2003 explored the concept of a clinical endocannabinoid deficiency (CECD) underlying the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis.” “Ethan B. Russo's paper of December 1, 2003 explored the concept of a clinical endocannabinoid deficiency (CECD) underlying the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis.”“Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions.” “Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions.” Smith SC, Wagner MS. Neuro Endocrinol Letter. 2014;35(3):198-201.
  25. 25. Bluett RJ. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psych 2014 Jul 8;4:e 408 • Pharmacological augmentation of central endogenous cannabinoid (eCB) signaling may be an effective therapeutic strategy to mitigate the adverse behavioral and physiological consequences of stress. • These studies provide further support that eCB- augmentation is a viable pharmacological strategy for the treatment of stress-related neuropsychiatric disorders. • Pharmacological augmentation of central endogenous cannabinoid (eCB) signaling may be an effective therapeutic strategy to mitigate the adverse behavioral and physiological consequences of stress. • These studies provide further support that eCB- augmentation is a viable pharmacological strategy for the treatment of stress-related neuropsychiatric disorders.
  26. 26. Inflammation and CBD • CBD tested on mice that had a version of RA – CBD reduced mouse inflammation by 50% at correct dosage – Malfait AM et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen- induced arthritis. PNAS vol 97 no 17, 9561-9566 • one dosage of CBD immediately following a heart attack can reduce infarct size by c. 66% – Durst R et al. Am J Physiol Heart Circ Physiol.2007Dec;293(6): H3602-7.
  27. 27. B These data suggest that anandamide blocks human breast cancer cell proliferation through CB1-like receptor-mediated inhibition of endogenous prolactin action at the level of prolactin receptor. These data suggest that anandamide blocks human breast cancer cell proliferation through CB1-like receptor-mediated inhibition of endogenous prolactin action at the level of prolactin receptor.
  28. 28. B Both endocannabinoids exhibited neuroprotective activity at LOWER dose, but were neurotoxic at higher dose. Both endocannabinoids exhibited neuroprotective activity at LOWER dose, but were neurotoxic at higher dose.
  29. 29. B CONCLUSIONS. This data shows that acute administration of CBD reduces resting BP and the BP increase to stress in humans, associated with increased HR. CONCLUSIONS. This data shows that acute administration of CBD reduces resting BP and the BP increase to stress in humans, associated with increased HR.
  30. 30. B “…due to its interaction with PPAR- gamma, CBD was observed to stimulate hippocampal neurogenesis.” “…due to its interaction with PPAR- gamma, CBD was observed to stimulate hippocampal neurogenesis.”
  31. 31. What does the literature say about… • Pain • Sleep • Anxiety • Seizures • IBS • ADHD
  32. 32. “Endocannabinoids, a group of less well--known endogenous bioactive lipids ... [are] able to influence both inflammation and pain.”
  33. 33. • are under circadian control • promote non-rapid eye movement sleep • promote REM by interacting with melanin- concentrating hormone neurons • restores sleep in a model of insomnia in rats Endocannabinoids sleep – 102 citations 3/4/2018
  34. 34. • cannabidiol (CBD), while representing a less specific pharmacological approach, may be another way to modulate eCBs and interacting neurotransmitter systems to alleviate anxiety. Endocannabinoids anxiety– 306 citations 3/4/2018
  35. 35. CONCLUSIONS: Our findings demonstrate that the deletion of Dagla [dacylgerol lipase alpha (DAGLalpha)] adversely affects the emotional state of animals and results in enhanced anxiety, stress, and fear responses. CONCLUSIONS: Our findings demonstrate that the deletion of Dagla [dacylgerol lipase alpha (DAGLalpha)] adversely affects the emotional state of animals and results in enhanced anxiety, stress, and fear responses.
  36. 36. Seizures “These data suggest the need for developing novel treatments using compounds that selectively target individual elements of the endocannabinoid signaling system. “These data suggest the need for developing novel treatments using compounds that selectively target individual elements of the endocannabinoid signaling system. 86 citations on “endocannabinoid system epilepsy” – 3/4/2018alsdkfj
  37. 37. Endocannabinoid system and IBS Hasenoehri C et al. The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease. Neurogastroenterol. Motil. 2016 Dec; 28(12):1765-1780. “Cannabinoid receptors and their endogenous ligands, the endocannabinoids, participate in the regulation of GI motility, secretion, and the maintenance of the epithelial barrier integrity.” “Cannabinoid receptors and their endogenous ligands, the endocannabinoids, participate in the regulation of GI motility, secretion, and the maintenance of the epithelial barrier integrity.” Endocannabinoid system irritable bowel syndrome – 26 citations - March 4, 2018
  38. 38. ADHD & the Endocannabinoid System • 18 citations in literature – March 4, 2018 – “adults with ADHD may represent a subgroup of individuals who experience a reduction of symptoms and no cognitive impairments following cannabinoid use.” • Cooper RE et al. Eur Neuropsychopharmacol. 2017 Aug; 27(8):795-808
  39. 39. • 30 adults with ADHD, placebo controlled study • Sativex Oromucosal spray was used. • “Adults with ADHD may represent a sub-group of individuals who experience a reduction of symptoms and no cognitive impairments following cannabinoid use.”
  40. 40. Bioavailability problems of commercial products • Commercial hemp oil – Not THC free. – Only 6% of what is ingested gets absorbed. – 90% is wasted. • Micellized hemp oil = 85% bioavailability – Onset of action drops from 1-2 hours down to 5 – 15 min.
  41. 41. Full Spectrum Hemp Oil NOT just CBD… • Cannabinoids • Terpenes • Flavonoids • Fatty Acids • Vitamins • Minerals 7
  42. 42. Micellation
  43. 43. Hemp oil and Ultracell
  44. 44. Legal in Indiana
  45. 45. Legal in Indiana
  46. 46. 50% absorption to average plasma level within 15 minutes.
  47. 47. New Ultracell Study • N = 20 • Up to 94% absorption of cannabinoids in 12 hours – 10.9 mg of CBD in Ultracell – - 8.3 mg back in the blood • Blood drawn every 15 minutes and then hourly out to 11 hours • 50% OF ULTRACELL was in the body in 10 – 15 min
  48. 48. • 2000 inappropriate online health claims; 1000 still online • www.truthinadvertising.org , 2017 • 158 direct selling companies • 62 sell nutritional supplements • 60/62 (97%) have made health claims that... • “their products can diagnose, treat, cure, prevent, or alleviate the symptoms of and/or reduce the risk of developing a multitude of diseases.” The Bottom Line: DON’T MAKE UNSUBSTANTIATED “HEALTH CLAIMS.”
  49. 49. Personal collection Louis B. Cady,
  50. 50. Contact information and slide resources Louis B. Cady, MD Cady Wellness Institute 4727 Rosebud Lane – Suite F Newburgh, IN 47630 USA Office (812) 429-0772 • www.cadywellness.com • info@cadywellness.com • www.facebook.com/cadywellnes • Twitter: @LouisCadyMD

×